Ionis Pharmaceuticals heads into this week's earnings report with short interest at an 11-month high and the analyst community in near-uniform target-cutting mode — a combination that frames today's results as a high-stakes inflection point for a stock already down 32% over the past month.
The short position has become the defining feature of the setup. Bears added aggressively in the week of July 21, with short interest jumping 21% over seven days to reach 11.9% of the free float — roughly 19.4 million shares. That move pushed the ORTEX short score to 56.9, its highest reading in the recent window, and reversed what had looked like a gradual wind-down from mid-July levels. The borrow market, however, offers little friction to new shorts: availability has actually loosened sharply, climbing to 1,509% — meaning roughly 15 shares are available to borrow for every one already lent out, a historically comfortable level. Borrowing costs confirm the same story, running at just 0.5% annualised, down roughly 30% over the past month. Bears can add cheaply and easily. What changed was the willingness to do so, not the cost.
Options traders are not particularly alarmed. The put/call ratio at 0.57 is actually slightly below its 20-day average of 0.60, a mild call-side lean that stands in contrast to the short-interest surge. There is no meaningful options-market panic here — which makes the short-interest build look more like a fundamental disagreement about the pipeline than a reflexive hedge. The PCR has ranged from 0.28 to 1.21 over the past year; the current reading is well within the normal band.
The Street has spent the past three weeks cutting targets but not convictions. The directional signal from analysts is clear: every firm that has moved in the past two weeks has trimmed their price target, with cuts ranging from $10 to $25 across Morgan Stanley (to $110), Barclays (to $90), Citigroup (to $100), Jefferies (to $90), and RBC (to $85). Guggenheim lowered its target to $89 on July 21 while holding its Buy. Only Wolfe Research moved on the rating itself, downgrading to Peer Perform on July 16. The consensus mean target sits at $91.65 — a 66% premium to where the stock trades at $55.30. That gap is enormous, and it reflects two things simultaneously: the Street still believes the pipeline has value, but it has also been systematically wrong on where the stock clears. The bear case — a Phase 3 miss on Wainua, partner-driven revenue uncertainty, and rising competition — has driven the 32% one-month drawdown that no target revision has fully caught up with.
Capital Research and Management stands as the largest institutional holder at 13% of shares, having added 3.5 million shares as of June 30 — a meaningful accumulation into the weakness. BlackRock and T. Rowe Price hold a combined 12% with only marginal changes. That institutional support sits alongside recent insider selling: the Chief Scientific Officer sold roughly $1.7 million in shares on July 7 at prices between $83 and $86, well above the current level. The net insider position over 90 days is technically positive in share terms, but the open-market sales from senior scientific leadership at materially higher prices adds a layer of caution the institutional inflows do not fully offset.
With earnings reported today, the structure of what comes next is less about quarterly revenue and more about whether management can offer any update on the pipeline catalysts — particularly bepirovirsen and the Wainua programme — that could close any portion of the 66% gap between the stock and analyst targets. The short position is large and freshly built; the borrow market is wide open; and peers BIIB and VRTX both posted modest weekly gains while IONS recovered only 3.6%. Watch for whether the short interest responds to whatever the earnings call delivers — at 11.9% of float, there is material covering potential if the narrative shifts.
See the live data behind this article on ORTEX.
Open IONS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
